Posted by Michael Wonder on 16 Jun 2023
U.S. Food and Drug Administration approves addition of positive data from Phase 3 VALOR-HCM study to Camzyos (mavacamten) label
15 June 2023 - VALOR-HCM is the second Phase 3 trial in which Camzyos demonstrated significant improvement in symptoms of obstructive HCM.
Bristol Myers Squibb today announced that the US FDA approved the supplemental new drug application to add positive data from the Phase 3 VALOR-HCM study to the US Prescribing Information for Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules).
